1 March 2023 - Pfizer and BioNTech today submitted an application to the US FDA for emergency use authorisation of ...
24 February 2023 - Pfizer and BioNTech today announced they have submitted a supplemental biologics license application to the US ...
22 February 2023 - Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial. ...
21 February 2023 - Icosavax today announced the US FDA has granted fast track designation for IVX-A12, a bivalent respiratory syncytial ...
21 February 2023 - US FDA has set an action date for August 2023. ...
20 February 2023 - Valneva today announced that the US FDA has completed a filing review of its biologics license ...
30 January 2023 - Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated ...
9 January 2023 - Commercial price is similar to Pfizer’s plans for after government contracting ends. ...
6 January 2023 - If approved, the vaccine would provide the broadest serotype coverage of any pneumococcal conjugate vaccine in infants ...
5 January 2023 - Breakthrough therapy designation for 24 valent investigational pneumococcal conjugate vaccine candidate based on positive topline proof of ...
28 December 2022 - Pfizer today announced that the US FDA accepted for review a biologics license application for its investigational ...
23 December 2022 - Valneva today announces that it has completed rolling submission of the biologics license application to the ...
13 December 2022 - Vaccine exclusively delivered with the PharmaJet Stratis needle-free injection system. ...
9 December 2022 - Pfizer and BioNTech today announced the companies have received fast track designation from the US FDA ...
8 December 2022 - Today, the US FDA amended the emergency use authorisations of the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 ...